The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Sanofi
Research Funding - Clovis Oncology
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; BeiGene; Clovis Oncology; Janssen-Cilag; Johnson & Johnson; Novartis; Sanofi
The effect of prior docetaxel (DOC) treatment on efficacy and safety of apalutamide (APA) plus androgen deprivation therapy (ADT) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) from TITAN.
 
Kim N. Chi
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Janssen; Merck; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Constellation Pharmaceuticals; Daiichi Sankyo; ESSA; Janssen; Merck; POINT Biopharma; Roche; Sanofi
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); ESSA (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - AstraZeneca; Novartis
 
Axel S. Merseburger
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Clovis Oncology; Ipsen; Janssen-Cilag; MSD Oncology; Takeda
Speakers' Bureau - Ipsen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Janssen-Cilag (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen; Janssen-Cilag
 
Mustafa Ozguroglu
Honoraria - Astellas Pharma; Janssen Oncology (Inst); Novartis
Consulting or Advisory Role - AstraZeneca; MSD Oncology
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Simon Chowdhury
No Relationships to Disclose
 
Anders Bjartell
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Janssen-Cilag; Merck; Sandoz
Speakers' Bureau - Astellas Pharma; Bayer; Janssen-Cilag
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Ferring (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Janssen-Cilag
 
Byung Chung
Honoraria - Astellas Pharma; Ipsen; JW Pharmaceutical; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Janssen; Myovant Sciences; Pfizer; Roche
 
Andrea Juliana Pereira de Santana Gomes
No Relationships to Disclose
 
Robert Given
Consulting or Advisory Role - Janssen Oncology
Speakers' Bureau - Bayer Schering Pharma; Janssen Oncology; Myovant Sciences
 
Álvaro Juárez
Honoraria - Astellas Pharma; Bayer; Bayer (Inst); Janssen Oncology; Janssen Oncology (Inst); Pfizer
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bayer (Inst); Exelixis (Inst); Janssen Oncology (Inst)
 
Hirotsugu Uemura
Honoraria - Bayer; Bristol-Myers Squibb Japan; Janssen; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Sanofi
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Eisai; Janssen; MSD; Pfizer
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Takeda (Inst)
 
Dingwei Ye
No Relationships to Disclose
 
Lawrence Ivan Karsh
Stock and Other Ownership Interests - Swan Valley Medical
Honoraria - Astellas Pharma; Bayer Health; Dendreon; Janssen; Pfizer
Consulting or Advisory Role - 3D Biopsy; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Ferring; Janssen; Pfizer; Vaxiion
Speakers' Bureau - Astellas Pharma; Bayer; Clovis Oncology; Janssen; Pfizer
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioXcel Therapeutics (Inst); Bristol-Myers Squibb (Inst); CU Optics (Inst); CUSP (Inst); Dendreon (Inst); Epizyme (Inst); Exact Sciences (Inst); Ferring (Inst); FKD Therapies (Inst); Genentech/Roche (Inst); Genomic Health (Inst); Janssen (Inst); Merck (Inst); Myovant Sciences (Inst); Nucleix (Inst); OncoCellMDx (Inst); Pfizer (Inst); Pharmatech/Veru (Inst); Precision Medicines (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Dendreon; Janssen; Pfizer
 
Benjamin Adam Gartrell
Honoraria - Janssen
Consulting or Advisory Role - Janssen
 
Sabine D. Brookman-May
Employment - Janssen Research & Development
Leadership - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Suneel Mundle
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Sharon Anne McCarthy
Employment - Janssen Oncology
Stock and Other Ownership Interests - Johnson and Johnson
 
Florence Lefresne
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Oliver Brendan Rooney
Employment - J&J
Stock and Other Ownership Interests - J&J
 
Amitabha Bhaumik
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; EMD Serono; Exelixis; Foundation Medicine; Genentech; Janssen; Lilly; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pharmacyclics; Seagen
Research Funding - AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Clovis Oncology (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics/Gilead (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Merck (Inst); Nektar (Inst); New Link Genetics/BlueLink Pharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); TRACON Pharma (Inst)